Theratechnologies Brief: Citing Acceleration of Phase 1 Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer With Enrollment of Next Cohort of Patients Underway at Higher Dose Level
Theratechnologies Brief: Citing Acceleration of Phase 1 Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer With Enrollment of Next Cohort of Patients Underway at Higher Dose Level
Theratechnologies簡報：引用蘇多西他賽增杜索肽治療晚期卵巢癌的1期試驗正在加速，下一批患者正在以更高的劑量入組
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊